Capricor Therapeutics (CAPR) Earnings Date, Estimates & Call Transcripts

$5.41
+0.26 (+5.05%)
(As of 04/26/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 9Estimated
Actual EPS
(Feb. 29)
-$0.02 Beat By $0.21
Consensus EPS
(Feb. 29)
-$0.23
Skip Charts & View Estimated and Actual Earnings Data

CAPR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CAPR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Capricor Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.11)($0.11)($0.11)
Q2 20241($0.32)($0.32)($0.32)
Q3 20241($0.31)($0.31)($0.31)
Q4 20241($0.17)($0.17)($0.17)
FY 20244($0.91)($0.91)($0.91)

CAPR Earnings Date and Information

Capricor Therapeutics last announced its earnings data on February 29th, 2024. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.21. The company earned $12.09 million during the quarter, compared to analysts' expectations of $5.80 million. Capricor Therapeutics has generated ($0.87) earnings per share over the last year (($0.87) diluted earnings per share). Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($0.83) to $0.12 per share. Capricor Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.

Capricor Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Estimated)
------- 
2/29/2024Q4 2023($0.23)($0.02)+$0.21($0.02)$5.80 million$12.09 million
11/14/2023Q3 2023($0.27)($0.25)+$0.02($0.25)$3.33 million$6.19 million
8/7/2023Q2 2023($0.34)($0.29)+$0.05($0.29)-$3.92 million
5/11/2023Q1 2023($0.32)($0.31)+$0.01($0.31)$1.00 million$2.99 million
3/15/2023Q4 2022-($0.31)($0.31)($0.31)$0.01 million$0.96 million
11/10/2022Q3 2022($0.28)($0.26)+$0.02($0.26)$0.42 million$1.59 million
8/10/2022Q2 2022($0.25)($0.29)($0.04)($0.29)--    
5/10/2022Q1 2022-($0.32)($0.32)($0.32)--
3/10/2022Q4 2021($0.19)($0.26)($0.07)($0.26)--    
11/8/2021Q3 2021($0.22)($0.17)+$0.05($0.17)--    
8/12/2021Q2 2021($0.23)($0.21)+$0.02($0.21)$0.21 million$0.20 million    
5/13/2021Q1 2021-($0.23)($0.23)($0.23)-$0.04 million

Capricor Therapeutics Earnings - Frequently Asked Questions

When is Capricor Therapeutics's earnings date?

Capricor Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on CAPR's earnings history.

Did Capricor Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Capricor Therapeutics (NASDAQ:CAPR) reported ($0.02) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.23) by $0.21. Learn more on analysts' earnings estimate vs. CAPR's actual earnings.

How much revenue does Capricor Therapeutics generate each year?

Capricor Therapeutics (NASDAQ:CAPR) has a recorded annual revenue of $25.18 million.

How much profit does Capricor Therapeutics generate each year?

Capricor Therapeutics (NASDAQ:CAPR) has a recorded net income of -$22.29 million. CAPR has generated -$0.87 earnings per share over the last four quarters.

What is Capricor Therapeutics's EPS forecast for next year?

Capricor Therapeutics's earnings are expected to grow from ($0.83) per share to $0.12 per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:CAPR) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners